Clinical trial NCT02308657: Multicenter Observational Study of Myotonic Dystrophy Type 1
Official title: A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myotonic Dystrophy Type 1
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: University of Florida
name: University of Kansas Medical Center
name: Ohio State University
name: Stanford University
name: National Institute of Neurological Disorders and Stroke (NINDS)
name: Biogen
name: Muscular Dystrophy Association
name: Myotonic Dystrophy Foundation
name: The Marigold Foundation
First posted: 2014-12-04
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Approximately 100 adult patients (18 to 70 years old, inclusive) with DM1 will be enrolled at 6 centers.

Brief summary: The purpose of the study is to determine the best ways to assess how people are affected by myotonic dystrophy type 1 (DM1). The study will assess walking speed, muscle strength, muscle size, myotonia, heart rhythm, mental efficiency, and overall health. Participants will complete questionnaires to record their ideas about how they are affected by DM1. The study will evaluate people with DM1 over 1 year to determine how the condition changes over time. The study will identify biomarkers of DM1. Biomarkers are laboratory measurements that show the effects of DM1 on a person's muscle tissue or blood. Biomarkers are needed in future studies to determine how DM1 may respond to treatments.

Detailed description: Participants in the study will come to the study site for 3 study visits. Each visit will take most of the day. Each visit will include a series of evaluations to determine how the person is affected by myotonic dystrophy. The results from the initial study visit will be compared to the second study visit after 3 months and the third study visit after 1 year. A small needle biopsy of a leg muscle will be performed at the first and second study visits (but not at the third visit). After the second study visit, participants will be asked to make a phone call every day for 30 days to report their symptoms and muscle strength (grip strength).

Eligibility criteria: Inclusion Criteria:

* Ability to understand the purpose and risks of the study and provide signed informed consent and authorization to use protected health information in accordance with national and local patient privacy regulations.
* Men and women, 18 to 70 years old, inclusive; body mass index ≤33.
* Onset of DM1 after age 10.
* Clinical diagnosis of DM1 based on research criteria or prior genetic testing with confirmation of CTG repeat length ≥70. A genetic test confirming DM1 is not required for entry. A DNA sample will be obtained from all subjects for DM1 genetic testing. If this test does not show an expanded repeat in the DM1 gene the subject will be withdrawn from the study.
* Ability to complete a 6 minute walk test (ankle-foot braces are allowed, but cane and walker are not allowed).

Exclusion Criteria:

* Clinically significant infections or medical illness from 30 days prior to Visit 1.
* History of, or abnormal laboratory values indicative of, significant medical, neurologic (other than DM1), or psychiatric disorders that might preclude participation in the study in the opinion of the Investigator.
* A recent history of any of the following conditions on routine blood screening: white blood cells \<3000, platelets \<100,000, hematocrit \<30%, symptomatic liver disease with serum albumin \<3 g/L, or creatinine \>1.5 mg%.
* Any of the following medical conditions: uncontrolled or insulin dependent diabetes mellitus, congestive heart failure, symptomatic cardiomyopathy, symptomatic coronary artery disease, cancer (other than skin cancer) within the prior 5 years, multiple sclerosis, or other serious medical illness.
* Myotonic dystrophy type 2 or other diseases that mimic the signs or symptoms of DM1. Coexistence of other neuromuscular disease.
* Thyroid dysfunction that is untreated (if on thyroid hormone replacement therapy, need to have adequate and stable replacement over the previous 6 months).
* Second or third degree heart block, atrial flutter, atrial fibrillation, ventricular tachycardia, or is receiving medication for the treatment of cardiac arrhythmia.
* Liver or kidney disease requiring ongoing treatment.
* Have a seizure disorder.
* Drug or alcohol abuse within 3 months of Visit 1.
* Women who are pregnant or who plan to become pregnant during the study's duration.
* Treatment with supplemental anabolic hormones (including testosterone, human recombinant growth hormone, human recombinant insulin like growth factor-1, other anabolic drug mixtures) during the previous 12 months.
* History of bleeding tendency or ongoing oral anticoagulation.
* Hypersensitivity to local anesthetics or components thereof to be used in the biopsy procedure.
* Participation in any investigational treatment study within 6 months prior to Visit 1.
* Inability or unwillingness to undergo any of the study-specific procedures or assessments, including needle muscle biopsies.
* Medical or other unspecified reasons that in the opinion of the Investigator makes the patient unsuitable for enrollment.
* Treatment with any of the following anti-myotonia medications within 8 weeks prior to Visit 1: phenytoin, carbamazepine, procainamide, disopyramide, nifedipine, acetazolamide, clomipramine, imipramine, mexiletine
* Treatment with corticosteroids within 8 weeks prior to Visit 1.

Primary outcomes:
measure: Needle Muscle Biopsy RNA Biomarkers
timeFrame: Baseline, 3 months
Secondary outcomes:
measure: Myotonia
timeFrame: Baseline, 3 months, 1 year
measure: Muscle Strength
timeFrame: Baseline, 3 months, 1 year
measure: Myotonic Dystrophy Health Index (MDHI)
timeFrame: Baseline, 3 months, 1 year
Other outcomes:
measure: Timed functional tests
timeFrame: Baseline, 3 months, 1 year
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
city: Bethesda
country: United States
facility: NIH
state: Maryland
city: Rochester
country: United States
facility: University of Rochester
state: New York
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
Study officials:
affiliation: University of Rochester
name: Charles A Thornton, MD
role: PRINCIPAL_INVESTIGATOR
References: